PerkinElmer Introduces Next Generation Cell Image Analysis and Management Software Platform to Help Streamline Drug Discovery Decision Making

PerkinElmer Introduces Next Generation Cell Image Analysis and Management Software Platform to Help Streamline Drug Discovery Decision Making

October 4, 2021 at 11:45 AM EDT

Signals Image Artist helps scientists process and analyze 3D cell imaging, phenotypic and cell painting data in hours vs. days or weeks

October 4, 2021

WHAT: PerkinElmer, Inc ., a global leader committed to innovating for a healthier world, today announced the launch of Signals Image Artist™ software, a next generation image analysis and management platform for drug discovery research. The new offering is designed to help scientists accurately process and analyze their high-content screening (HCS) and cellular imaging data in a matter of hours vs. days or weeks, so they can make more informed decisions  faster. The Signals Image Artist offering is part of the Company’s leading, Signals Informatics portfolio.

HOW: The Signals Image Artist software is designed expressly for the big data demands drug discovery labs are working with today, including 3D cell, phenotypic and cell painting images. Its intuitive user interface requires minimal user training and the software supports multiple users processing, analyzing, sharing, and storing information at the same time without compromised performance.

Cloud and on-premise deployment options are available as is scalable storage capacity to expand as lab needs change.

The new software is a strong complement to PerkinElmer’s HCS workflow solution that includes the Opera Phenix® Plus and Operetta® CLS High-Content Screening System, PhenoVue™ reagents, PhenoPlate™ microplates, automation and Signals Screening™ platform (soon to be re-branded Signals VitroVivo™).  With the pre-built integration of the Signals Image Artist software, users of the Signals VitroVivo platform can make a seamless handover of data coming from HCS experiments to perform secondary analysis like machine learning-supported clustering and statistical analysis. This integration helps scientists gain insights into time series, potential treatment and phenotypic changes in the drug candidates they are working on, and allows results and supporting workflows to be shared.

The Signals Image Artist software is also compatible with all major HCS and cell imaging systems on the market today -- supporting users in multivendor lab environments.

WHY: “Today’s drug discovery labs are generating massive amounts of image data driven by a rise in the use of physiologically relevant models and the increasing adoption of cell painting and phenotypic screening approaches to try and reduce clinical trial failure rates,” said Alan Fletcher, senior vice president of life science, PerkinElmer. “Our new Signals Image Artist  platform is designed to help drug discovery researchers drive more efficiently and effectively towards the next new novel therapeutic candidate by dramatically speeding up image processing, delivering quick and accurate data, and fostering easier collaboration.”

MORE: PerkinElmer’s HCS solutions are part of a comprehensive portfolio for life science and drug discovery and development. For more information, please visit.

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 15,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at


Media Contact
Jennifer McNeil

1 508.380.2902

Related Links

IR Contact
(781) 663 - 6900
940 Winter Street
Waltham, MA 02451
United States

Transfer Agent

Mailing addresses
Correspondence should be mailed to:
P.O. Box 505000
Louisville, KY 40233

Overnight correspondence should be sent to:
462 South 4th Street, Suite 1600
Louisville, KY 40202

Shareholder website
Shareholder online inquiries